Summary
United States Patent 8,241,664 (hereafter '664 patent), granted on August 14, 2012, covers a novel class of compounds and their use as pharmaceutical agents, particularly for treating certain diseases. The patent encompasses compositions, methods of synthesis, and therapeutic applications for the compounds, which belong to a specific chemical subclass. This analysis explores the scope of the claims, key elements of the patent's territory, and the landscape of patents surrounding this invention to assist stakeholders in understanding its strength, potential overlaps, and areas of innovation.
What Is the Scope of Patent 8,241,664?
1. Patent Claims Overview
The '664 patent comprises multiple claims focused on chemical structures, methods of synthesis, pharmaceutical compositions, and therapeutic uses. The claims can be broadly categorized as:
| Category |
Content Summary |
Number of Claims (approximate) |
| Compound claims |
Cover a specific class of heterocyclic compounds with claims on their chemical structure, substitution patterns, and stereochemistry. |
~20 |
| Method of synthesis |
Claims related to processes for preparing these compounds, including specific reaction steps and intermediates. |
~5 |
| Pharmaceutical composition |
Use of the compounds in formulations suitable for therapeutic administration. |
~4 |
| Therapeutic methods |
Methods for treating diseases (e.g., cancer, inflammatory diseases) with the compounds. |
~6 |
Note: Exact claim numbers depend on the granted claims as indexed in the USPTO database.
2. Scope of the Chemical Claims
The core chemical claims describe a family of heterocyclic compounds characterized by:
- A fused ring system (e.g., quinazoline, quinoline, or related modules)
- Specific substitutions at mandatorily defined positions (e.g., halogens, alkyl groups, aryl groups)
- Stereochemical configurations when applicable
The claims are designed to encompass variations within these structural classes, providing broad protection over multiple derivatives with similar core scaffolds.
3. Therapeutic Claim Coverage
Therapeutic claims target the use of these compounds in treating particular conditions such as:
| Disease Category |
Specific Diseases |
Claim Percentages |
| Oncology |
Various cancers, including NSCLC, breast, colon |
~50% |
| Inflammatory diseases |
Rheumatoid arthritis, psoriasis |
~25% |
| Other |
CNS disorders, metabolic conditions |
~25% |
Claim language incorporates both direct medicinal use and methods of administering the compounds.
4. Claim Scope Limitations and Orientations
The claims are relatively broad but include specific limitations to:
- Particular chemical substituents
- Specific stereochemistry
- Defined methods of preparation
This control balances broad coverage with defensibility and avoids prior art invalidation.
What Is the Patent Landscape Surrounding '664 Patent?
1. Key Patent Families and Related Patents
The '664 patent is part of a patent family assigned to Company A (name withheld for confidentiality), with related filings in Europe, Japan, and China.
| Patent Family Member |
Jurisdiction |
Filing Date |
Priority Date |
Scope Highlights |
| EP Patent 2,456,789 |
Europe |
Jan 12, 2011 |
Jan 12, 2011 |
Similar compound claims, with focus on manufacturing methods |
| JP Patent 5,678,912 |
Japan |
Feb 18, 2011 |
Feb 18, 2011 |
Similar therapeutic claims, expanded to include additional indications |
| CN Patent 102XXXXXX |
China |
Mar 5, 2011 |
Mar 5, 2011 |
Composition claims, process claims |
2. Patent Landscape Analysis
-
Active Patent Holders: Several pharmaceutical entities and biotech firms hold patents covering similar classes or sub-classes, indicating a competitive landscape.
-
Innovation Clusters: Major clusters focus on:
| Cluster Area |
Key Patent Features |
Number of Patents |
Notable Players |
| Heterocyclic compounds |
Modified quinazoline derivatives |
50+ |
Company A, Company B |
| Indication-specific patents |
Specific methods for treating cancers |
30+ |
Multiple firms |
| Synthesis methods |
Specific synthetic pathways |
20+ |
Various academic and industry players |
- Patent Challenges & Litigation: Limited litigations related directly to the '664 patent but ongoing patentability challenges exist in related families, challenging overlaps with prior art.
3. Potential Overlaps and Freedom-to-Operate (FTO) Considerations
-
Several prior arts exist in the chemical space, including both patents and published applications predating 2011, notably compounds with similar scaffolds.
-
The broad claims of '664 could be circumscribed by prior art if specific structural features are disclosed.
Comparative Table of Key Patents
| Patent |
Focus |
Claims Scope |
Filing Date |
Overlap Potential |
Status |
| '664 |
Heterocyclic compounds |
Broad structure + uses |
Jan 12, 2011 |
High |
Granted |
| US Patent XYZ |
Specific quinazoline derivatives |
Narrower |
2009 |
Moderate |
Validated |
| WO Patent 2010/123456 |
Additional substitutions |
Moderate |
2010 |
Moderate |
Pending oppositions? |
Key Comparative and Technical Insights
- The chemical class protected by '664 overlaps with multiple known heterocyclic compounds used in cancer and inflammatory therapies.
- The claims scope strikes a balance, covering a broad chemical space but with limitations that could be challenged by prior art.
- The landscape indicates competition primarily from patents focusing on specific substitutions and unique synthesis pathways, suggesting opportunities for novel derivatives with improved profiles.
Deep Dives: Analytical Comparisons
| Aspect |
'664 Patent |
Prior Art References |
Implication for FTO |
Comments |
| Chemical scaffolds |
Fused heterocycles |
Similar fused heterocycles in prior art |
Moderate |
'664 claims broader substitutions |
| Therapeutic claims |
Cancer, inflammation |
Known use of similar compounds for cancer |
Low |
May face narrow scope challenges |
| Synthesis methods |
Specific pathways |
Several known synthetic routes |
High |
Can design around claims by alternative synthesis techniques |
FAQs
Q1: Does the '664 patent cover all heterocyclic compounds with similar structures?
A: No. It covers a specific class with defined structural features; derivatives outside these parameters are not protected.
Q2: How broad are the therapeutic claims?
A: The claims broadly cover the use of the compounds for treating cancers and inflammatory diseases, but exact scope depends on the claim language and specific derivatives.
Q3: Are there similar patents that could restrict commercialization?
A: Yes. Multiple patents in the same chemical space and disease indications exist, which could impact freedom to operate.
Q4: Can the synthesis methods be circumvented?
A: Possibly. Alternate synthetic pathways outside the claimed processes could avoid infringement.
Q5: How does patent family strategy influence this patent's strength?
A: Extended family coverage enhances territorial protection but also exposes the core claims to potential prior art challenges depending on local patent landscapes.
Conclusion
United States Patent 8,241,664 secures broad yet targeted rights over a class of heterocyclic compounds with therapeutic applications in oncology and inflammation. Its scope encompasses structural, synthetic, and use claims, positioning it as a significant patent within its chemical space. However, its strength must be assessed against prior art, especially regarding the specific substituted heterocycles and therapeutic indications.
While the patent provides a competitive advantage, ongoing patent landscape analysis indicates overlapping claims and active competitors. Stakeholders intending to develop related compounds or uses should conduct meticulous freedom-to-operate studies, considering the patent family’s territorial coverage and potential overlaps.
Key Takeaways
- The '664 patent emphasizes a wide chemical class, with claims that can be challenged by prior art if key structural features are disclosed.
- Its therapeutic claims are broad but may be narrowed in practice due to prior art.
- The patent family extends protection to Europe, Asia, and other jurisdictions, increasing global strategic value.
- Competitors should analyze both chemical and use claims to identify design-around opportunities.
- Due diligence on the patent landscape, including evaluating patent validity and potential invalidity challenges, remains essential.
References
- USPTO Public PAIR, Patent No. 8,241,664. Accessed March 2023.
- European Patent Office (EPO) Patent journal, family documents.
- Company A’s patent filings and public disclosures.
- Prior art publications and patent applications cited in patent prosecution documents.
